Edward Galli – DELiver Therapeutics

Ponce Aurora Appoints Former Estee Lauder Executive as Chief Commercial Officer Ahead of Longevity Product Launches

Ponce Aurora is developing consumer products powered by its proprietary MitoXcel™ Technology, the first information- and AI-driven mitochondrial-targeted geropeptides addressing a fundamental cause of aging. Appointment strengthens leadership team to drive market readiness for YUUTH- and…

Edward Galli In Press Releases

PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting

PrintBio, a regenerative medicine and bioprinting company, today announced its participation in a major ARPA-H PRINT Program initiative aimed at addressing the nation’s growing organ shortage through the development of…

Edward Galli In Upcoming Events

Baylor College of Medicine Inaugural Biotechnology and Healthcare Innovation Forum

Date: Tuesday, October 7th 2025 Location: TMC3 Collaborative Building (Atrium)7255 Helix Park Ave, Houston, TX 77030 8:00 a.m. Registration Opens 8:30 a.m. Opening Remarks ...

Edward Galli In News

Deliver Pharmaceuticals Presents at the 2024 Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting

Dr. Kevin Slawin, MD, Founder, Chairman and CEO of Deliver Therapeutics, Inc., presented the company at this year’s Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting held at The Alexandria…

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

GoodZ.Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.Nature Medicine.2018

/wp-content/uploads/2024/07/GoodZ.Single-cell-developmental-classification-of-B-cell-precursor-acute-lymphoblastic-leukemia-at-diagnosis-reveals-predictors-of-relapse.Nature-Medicine.2018.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

LeonardJ.Aurora A kinase as a target for therapy in TCF3-HLF rearranged ALL Haematologica 2021

/wp-content/uploads/2024/07/LeonardJ.Aurora-A-kinase-as-a-target-for-therapy-in-TCF3-HLF-rearranged-acute-lymphoblastic-leukemia.Haematologica.2021.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

OkabeS. Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells.Oncotarget.2018

/wp-content/uploads/2024/07/OkabeS.-Therapeutic-targeting-of-Aurora-A-kinase-in-Philadelphia-chromosome-positive-ABL-tyrosine-kinase-inhibitor-resistant-cells.Oncotarget.2018.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

RobertsKG.Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia.NEJM.2014

/wp-content/uploads/2024/07/RobertsKG.Targetable-Kinase-Activating-Lesions-in-Ph-like-Acute-Lymphoblastic-Leukemia.NEJM_.2014.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

WarschW. JAK of all trades- JAK2-STAT5 as novel therapeutic targets in BCR-ABL+ chronic myeloid leukemia.Blood.2013

/wp-content/uploads/2024/07/WarschW.-JAK-of-all-trades-JAK2-STAT5-as-novel-therapeutic-targets-in-BCR-ABL11-chronic-myeloid-leukemia.Blood_.2013.pdf

Edward Galli In Acute Lymphoblastic Leukemia, Scientific Publications, Tyrosine Kinase Inhibitors

YuanH.Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.Carcinogenesis.2012

/wp-content/uploads/2024/07/YuanH.Overcoming-CML-acquired-resistance-by-specific-inhibition-of-Aurora-A-kinase-in-the-KCL-22-cell-model.Carcinogenesis.2012.pdf